Skip to main content

Table 1 Characteristics of patients

From: The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Characteristic Cohort 1 N (%) Cohort 2 N (%) Cohort 3 N (%)
No. of patients, N 60 14 9
Sex
 Male 42 (70 %) 8 (57.1 %) 6 (66.7 %)
 Female 18 (30 %) 6 (42.9 %) 3 (33.3 %)
Age, median years (range) 54 (27–81) 59.5(40–76) 65 (42–82)
Tumor classification
 Cholangiocarcinoma 10 (16.7 %) 0 2 (22.2 %)
 Colon cancer 7 (11.7 %) 1 (7.1 %) 0
 Gastric cancer 7 (11.7 %) 0 0
 Lung cancer 11 (18.3 %) 4 (28.6 %) 2 (22.2 %)
 Primary liver cancer 25 (41.7 %) 1 (7.1 %) 2 (22.2 %)
 Other 0 8 (57.1 %) 3 (33.3 %)
TNM staging
 Stage I 3 (5 %) 1 (7.1 %) 2 (22.2 %)
 Stage II 4 (6.7 %) 0 1 (11.1 %)
 Stage IIIA 12 (20 %) 2 (14.3 %) 1 (11.1 %)
 Stage IIIB 2 (3.3 %) 0 0
 Stage IIIC 9 (15 %) 4 (28.6 %) 1 (11.1 %)
 Stage IV 27 (45 %) 6 (42.9 %) 3 (33.3 %)
 Missing data 3 (5 %) 1 (7.1 %) 1 (11.1 %)
Adjuvant therapeutic strategies
 Without 24 (40 %) 5 (35.7 %) 7 (77.8 %)
 With 36 (60 %) 9 (64.3 %) 2 (22.2 %)
 Chemotherapy 18 (30 %) 6 (42.9 %) 1 (11.1 %)
 Radiation therapy 8 (13.3 %) 1 (7.1 %) 1 (11.1 %)
 Physiotherapy 2 (3.3 %) 0 1 (11.1 %)
 Interventional treatment 9 (15 %) 2 (14.3 %) 0
 Molecular targeted therapy 2 (3.3 %) 1 (7.1 %) 0